01 January 1998
Relationship between LPS E. coli and Intralipid in the influence of peripheral blood neutrophils examined by the NBT reduction tests
Ewa Pawłowska, Gabriel TurowskiMed Sci Monit 1998; 4(1): BR57-63 :: ID: 502827
Abstract
The effect of LPS E. coli in different concentrations: 0.2, 1.0, 2.0, 4.0, 5.0 µg in constant volume of 0.01 ml of KRB and of Intralipid (ILP) in different dosages: 0.5, 1.0, 1.5, 2.0, 3.0 mg in 0.01 ml KRB, and also the mutual influence of LPS E. coli and Intralipid on metabolic activity of neutrophils reduction tests of sodium salt of nitroblue tetrazolium (NBT) were used.Stimulating effect of LPS E. coli was depended on used dosage. Dosages 0.2-1.0 µg of LPS proved to be insufficient for the stimulation of neutrophils. However statistically significant differences, in comparison to control, were ascertained for dosages 2.0-5.0 µg of LPS. Intralipid caused stimulation of neutrophils conditioned by size of used dosage. Obtained results of NBT test, stimulated by different ILP dosages, were highly statistically significant in comparison to control results. In combine use of ILP and LPS, for small dosages of LPS (o, 2-2.0 µg) stimulation was caused by ILP. In the use of 5.0 µg dosage of LPS statistically significant differences, in results of influence of LPS and ILP used together, in comparison to results of effect of LOPS, as well as ILP, when those factors worked separately were ascertained. It may point to stimulating effect of both factors combined on the metabolic activity of neutrophils.he research did not show a function of Intralipid in the neutralization of LPS E. coli. The experiment enable the choice of dosages: 4.0 µg LPS E. coli, and 2.0 mg of Intralipid as optimal for farther research of role of neutrophils in neutralization of endotoxin.
Keywords: Neutrophils, endotoxin (LPS), Intralipid (ILP), NBT reduction test
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952